Activity of synthetic peptides against Chlamydia

Abstract

The in vitro activity of six synthetic peptides against 36 strains of Chlamydia from different origins was investigated. Clavanin MO (CMO) proved to be the most active peptide, reducing the inclusion number of all Chlamydia strains from eight different species tested by ≥50% at 10 µg mL . Mastoparan L showed an equal activity against C. trachomatis, C. pneumoniae, C. suis, and C. muridarum, but did not exert any inhibitory effect against C. psittaci, C. pecorum, C. abortus, and C. avium even at 80 µg mL . These data suggest that CMO could be a promising compound in the prevention and treatment of chlamydial infections.

Mini Review: Antimicrobial Control of Chlamydial Infections in Animals: Current Practices and Issues

“…The emergence of antibiotic resistance should be the driver for development and application of new antichlamydials in veterinary medicine. Efforts for these are already underway, including in animals (Lawrence et al, 2016), exploiting a range of strategies to target Chlamydia -specific cell structures and/or known virulence factors (Ur-Rehman et al, 2012; Marti et al, 2014; Koroleva et al, 2015; Rahn et al, 2016; Donati et al, 2017; Papa et al, 2017; Figure 1). Regardless of years of research into chlamydia control through immunoprophylaxis there are almost no viable chlamydial vaccines to date.…”